<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2021-2985</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-2985</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОСТРЫЙ КОРОНАРНЫЙ СИНДРОМ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ACUTE CORONARY SYNDROME</subject></subj-group></article-categories><title-group><article-title>Возраст-ассоциированный уровень маркеров фиброза миокарда и хемокинов у пациентов с острым коронарным синдромом</article-title><trans-title-group xml:lang="en"><trans-title>Age-associated level of myocardial fibrosis markers and chemokines in patients with acute coronary syndrome</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7321-6529</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Осипова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Osipova</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Осипова Ольга Александровна — доктор медицинских наук, профессор кафедры госпитальной терапии Медицинского института.</p><p>Белгород.</p><p>Тел.: 8 (915) 575-89-69</p></bio><bio xml:lang="en"><p>Belgorod.</p><p>Tel.: 8 (915) 575-89-69</p></bio><email xlink:type="simple">osipova@bsu.edu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2722-7702</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Головин</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Golovin</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Головин Андрей Иванович — аспирант 2 курса Медицинского института.</p><p>Белгород.</p></bio><bio xml:lang="en"><p>Belgorod.</p></bio><email xlink:type="simple">723282@bsu.edu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6862-0829</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белоусова</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Belousova</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Белоусова Оксана Николаевна — доктор медицинских наук, профессор, профессор кафедры госпитальной терапии Медицинского института.</p><p>Белгород.</p></bio><bio xml:lang="en"><p>Belgorod.</p></bio><email xlink:type="simple">belousova_on@bsu.edu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9946-3675</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Землянский</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zemlyansky</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Землянский Олег Алексеевич — доктор медицинских наук, профессор, заведующий кафедрой микробиологии Медицинского института.</p><p>Белгород.</p></bio><bio xml:lang="en"><p>Belgorod.</p></bio><email xlink:type="simple">zemlyansky@bsu.edu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5308-8072</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Голивец</surname><given-names>Т. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Golivets</surname><given-names>T. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Голивец Татьяна Павловна — доктор медицинских наук, профессор, заведующий кафедрой госпитальной терапии Медицинского института.</p><p>Белгород.</p></bio><bio xml:lang="en"><p>Belgorod.</p></bio><email xlink:type="simple">golivets@bsu.edu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8876-0343</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Константинов</surname><given-names>С. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Konstantinov</surname><given-names>S. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Константинов Сергей Леонидович — заведующий кардиологическим отделением № 2.</p><p>Белгород.</p></bio><bio xml:lang="en"><p>Belgorod.</p></bio><email xlink:type="simple">Konstantinov5@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Белгородский государственный национальный исследовательский университет</institution></aff><aff xml:lang="en"><institution>National Research University “Belgorod State University”</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Белгородская областная клиническая больница Святителя Иоасафа</institution></aff><aff xml:lang="en"><institution>St. Ioasaph Belgorod Regional Clinical Hospital</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>21</day><month>07</month><year>2021</year></pub-date><volume>20</volume><issue>5</issue><fpage>2985</fpage><lpage>2985</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Осипова О.А., Головин А.И., Белоусова О.Н., Землянский О.А., Голивец Т.П., Константинов С.Л., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Осипова О.А., Головин А.И., Белоусова О.Н., Землянский О.А., Голивец Т.П., Константинов С.Л.</copyright-holder><copyright-holder xml:lang="en">Osipova O.A., Golovin A.I., Belousova O.N., Zemlyansky O.A., Golivets T.P., Konstantinov S.L.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/2985">https://cardiovascular.elpub.ru/jour/article/view/2985</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить возраст-ассоциированные особенности концентрации маркеров фиброза и моноцитарного хемоаттрактантного белка 1 (МСР-1) у больных острым коронарным синдромом с подъемом сегмента ST (OKCпST) в момент манифестации.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Обследовано 140 больных OKCпST в момент манифестации. В зависимости от возраста больные были разделены на группы: 42 человека — среднего возраста, 50 — пожилого, 48 — старческого. Контрольную группу (КГ) составили 20 человек без сердечно-сосудистой патологии. Уровень металлопротеиназы-9 (ММП-9), тканевого ингибитора матриксных металлопротеиназ-1 (ТИМП-1), МСР-1 определяли методом иммуноферментного анализа. Статистическая обработка проведена с использованием программного обеспечения “MATLAB 2020”.</p></sec><sec><title>Результаты</title><p>Результаты. Установлено, что у больных OKCпST в момент манифестации уровень ММП-9 у больных в среднем возрасте выше, чем в КГ в 2,9 раза (р&lt;0,001), пожилом — в 4,1 раза (р&lt;0,001), старческом — в 6 раз (р&lt;0,001). Обнаружена сильная прямая связь между возрастом и уровнем ММП-9 (r=0,86088, р&lt;0,001). Уровень ТИМП-1 был выше у всех больных (р&lt;0,05) по сравнению с КГ, выявлена сильная прямая взаимосвязь между уровнем ММП-9 и ТИМП-1 (r=0,7801; р&lt;0,01). Соотношение ММП-9/ТИМП-1 было выше в группе лиц среднего возраста на 85,7% (р&lt;0,05), пожилого — в 1,2 раза (р&lt;0,001), старческого — в 2,3 раза (р&lt;0,001) по сравнению с КГ. MCP-1 был повышен во всех возрастных группах (p&lt;0,001). Обнаружена прямая корреляционная связь между уровнем MCP-1 и ММП-9 (r=0,726, p&lt;0,001).</p></sec><sec><title>Заключение</title><p>Заключение. У больных OKCnST в момент манифестации выявлено возраст-ассоциированное увеличение по сравнению с контролем концентрации ММП-9 и соотношения ММП-9/ТИМП-1, что свидетельствует о преобладании маркера деградации межклеточного матрикса у больных с ОКС, при этом повышение уровня ММП-9, возможно, индуцировано хемокином MCP-1.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study age-related specifics of the concentration of fibrosis markers and monocyte chemotactic protein-1 (MCP-1) in patients with ST-segment elevation acute coronary syndrome (STE-ACS).</p></sec><sec><title>Material and methods</title><p>Material and methods. A total of 140 STE-ACS patients were examined. Depending on the age, participants were divided into following groups: middle age — 42 patients, elderly — 50 patients, senile — 48 patients. The control group (CG) consisted of 20 people without cardiovascular disease. The level of matrix metallopeptidase 9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), MCP-1 was determined by enzyme immunoassay. Statistical processing was carried out using the MATLAB 2020software.</p></sec><sec><title>Results</title><p>Results. It was found that in STE-ACS patients, the MMP-9 level in middle-aged patients is 2,9 times higher than in the CG (p&lt;0,001), elderly — 4,1 times (p&lt;0,001), senile — 6 times (p&lt;0,001). A strong direct relationship was found between age and MMP-9 level (r=0,86088, p&lt;0,001). The TIMP-1 level was higher in all patients (p&lt;0,05) compared with CG. A strong direct relationship was found between levels of MMP-9 and TIMP-1 (r=0,7801; p&lt;0,01). The MMP-9/TIMP-1 ratio was higher in the group of middle-aged people by 85,7% (p&lt;0,05), elderly — 1,2 times (p&lt;0,001), senile — 2,3 times (p&lt;0,001) compared to CG. MCP-1 was elevated in all age groups (p &lt;0,001). A direct correlation was found between levels of MCP-1 and MMP-9 (r=0,726, p&lt;0,001).</p></sec><sec><title>Conclusion</title><p>Conclusion. In STE-ACS patients, an age-associated increase in concentrations of MMP-9 and MMP-9/TIMP-1 ratio was found in comparison with CG, which indicates the predominance of intercellular matrix degradation marker in patients with ACS. At the same time, MMP-9 increase is possibly induced by MCP-1.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>маркеры фиброза миокарда</kwd><kwd>матриксная металлопротеиназа-9</kwd><kwd>тканевой ингибитор матриксной металлопротеиназы-1</kwd><kwd>моноцитарный хемоаттрактантный белок 1</kwd><kwd>острый коронарный синдром с подъемом сегмента ST</kwd></kwd-group><kwd-group xml:lang="en"><kwd>myocardial fibrosis markers</kwd><kwd>matrix metalloproteinase-9</kwd><kwd>tissue inhibitor of metalloproteinase-1</kwd><kwd>monocyte chemotactic protein-1</kwd><kwd>ST-segment elevation acute coronary syndrome</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Авторы благодарят сотрудников кафедры иностранных языков и профессиональной коммуникации Института межкультурной коммуникации и международных отношений Григоренко Н. В. и Мережко А.А. за помощь в создании текста данной статьи.</funding-statement><funding-statement xml:lang="en">The authors are grateful to the staff of the Department of Foreign Languages and Professional Communication of the Institute of Cross-cultural Communications and International Relations N.V. Grigorenko and A.A. Merezhko for help in creating the text.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Gach O, El HZ, Lancellotti P. Acute coronary syndrome. Rev Med Liege. 2018;73(5-6):243-50.</mixed-citation><mixed-citation xml:lang="en">Gach O, El HZ, Lancellotti P. Acute coronary syndrome. Rev Med Liege. 2018;73(5-6):243-50.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Осипова О. А., Гостева Е. В., Чефранова Ж. Ю. и др. Влияние фармакотерапии на динамику маркеров обмена коллагена у больных хронической сердечной недостаточностью с промежуточной фракцией выброса на фоне ишемической болезни сердца в старших возрастных группах. Кардиоваскулярная терапия и профилактика. 2020;19(5):2651. doi:10.15829/1728-8800-2020-2651.</mixed-citation><mixed-citation xml:lang="en">Osipova OA, Gosteva EV, Chefranova ZYu, et al. Effect of therapy on the dynamics of collagen metabolism markers in older patients with heart failure with mid-range ejection fraction and coronary artery disease. Cardiovascular Therapy and Prevention. 2020;19(5):2651. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Libby P, Pasterkamp G, Crea F, Jang IK. Reassessing the mechanisms of acute coronary syndromes. Circ Res. 2019;4;124(1):150-60. doi:10.1161/CIRCRESAHA.118.311098.</mixed-citation><mixed-citation xml:lang="en">Libby P, Pasterkamp G, Crea F, Jang IK. Reassessing the mechanisms of acute coronary syndromes. Circ Res. 2019;4;124(1):150-60. doi:10.1161/CIRCRESAHA.118.311098.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Осипова О.А., Нагибина А. И., Комисов А. А. и др. Патоморфологические механизмы регуляции образования миокардиального фиброза у больных хронической сердечной недостаточностью на фоне ишемической болезни сердца. Журнал сердечная недостаточность. 2016;5(98):357-64. doi:10.18087/RHFJ.2016.5.2137.</mixed-citation><mixed-citation xml:lang="en">Osipova OA, Nagibina AI, Komisov AA, et al. Pathomorphological mechanisms for regulation of myocardial fibrosis formation in patients with chronic heart failure with underlying ischemic heart disease. J Heart Failure. 2016;5(98):357-64. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kumric M, Borovac JA, Martinovic D, et al. Circulating biomarkers reflecting destabilization mechanisms of coronary artery plaques: are we looking for the impossible? Biomolecules. 2021;11(6):881. doi:10.3390/biom11060881.</mixed-citation><mixed-citation xml:lang="en">Kumric M, Borovac JA, Martinovic D, et al. Circulating biomarkers reflecting destabilization mechanisms of coronary artery plaques: are we looking for the impossible? Biomolecules. 2021;11(6):881. doi:10.3390/biom11060881.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lahdentausta L, Leskela J, Winkelmann A, et al. Serum MMP-9 diagnostics, prognostics, and activation in acute coronary. J Cardiovasc Transl Res. 2018;11(3):210-20. doi:10.1007/s12265-018-9789-x.</mixed-citation><mixed-citation xml:lang="en">Lahdentausta L, Leskela J, Winkelmann A, et al. Serum MMP-9 diagnostics, prognostics, and activation in acute coronary. J Cardiovasc Transl Res. 2018;11(3):210-20. doi:10.1007/s12265-018-9789-x.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Lahdentausta L, Sorsa T, Pesonen E, Pussinen P. The use of serum MMP-9 and TIMP-1 in acute coronary syndrome. J Cardiovasc Transl Res. 2018;11(6):526-27. doi:10.1007/s12265-018-9833-x.</mixed-citation><mixed-citation xml:lang="en">Lahdentausta L, Sorsa T, Pesonen E, Pussinen P. The use of serum MMP-9 and TIMP-1 in acute coronary syndrome. J Cardiovasc Transl Res. 2018;11(6):526-27. doi:10.1007/s12265-018-9833-x.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Freitas IA, Lima NA, Silva GBD Jr, et al. Novel biomarkers in the prognosis of patients with atherosclerotic coronary artery disease. Port Cardiol (Engl Ed). 2020;39(11):667-72. doi:10.1016/j.repc.2020.05.010.</mixed-citation><mixed-citation xml:lang="en">Freitas IA, Lima NA, Silva GBD Jr, et al. Novel biomarkers in the prognosis of patients with atherosclerotic coronary artery disease. Port Cardiol (Engl Ed). 2020;39(11):667-72. doi:10.1016/j.repc.2020.05.010.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Осипова О. А., Плаксина К.Г., Комисов А.А. и др. Патогенетические механизмы участия межклеточного матрикса миокарда в ремоделировании сердца у больных хронической сердечной недостаточностью. Научные ведомости Белгородского государственного университета. Серия: Медицина. Фармация. 2015;22(219):18-25.</mixed-citation><mixed-citation xml:lang="en">Osipova OA, Plaksina KG, Komiksov AA, et al. Pathogenetic mechanisms of the involvement of the intercellular matrix of the myocardium in the remodeling of the heart in patients with chronic heart failure. Scientific Bulletin of the Belgorod State University. Series: Medicine. Pharmacy. 2015;22(219):18-25. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Krebber MM, van Dijk CGM, Vernooij RWM, et al. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2020;21(18):6742. doi:10.3390/ijms21186742.</mixed-citation><mixed-citation xml:lang="en">Krebber MM, van Dijk CGM, Vernooij RWM, et al. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2020;21(18):6742. doi:10.3390/ijms21186742.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Осипова О. А., Гостева Е. В., Ильницкий А. Н., и др. Влияние фармакотерапии на обмен коллагена у больных старческого возраста c сердечной недостаточностью и промежуточной фракцией выброса. Успехи геронтологии. 2020;33(5):956-63. doi:10.34922/AE.2020.33.5.018.</mixed-citation><mixed-citation xml:lang="en">Osipova OA, Gosteva EV, Ilnitsky AN, et al. Effect of pharmacotherapy on collagen metabolism in elderly patients with heart failure and intermediate ejection fraction. Advances in gerontology. 2020;33(5):956-63. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Franco-Pelaez JA, Martm-Reyes R, Pello-Lazaro AM, et al. Monocyte Chemoattractant Protein-1 Is an Independent Predictor of Coronary Artery Ectasia in Patients with Acute Coronary Syndrome. J Clin Med. 2020;9(9):3-37. doi:10.3390/jcm9093037.</mixed-citation><mixed-citation xml:lang="en">Franco-Pelaez JA, Martm-Reyes R, Pello-Lazaro AM, et al. Monocyte Chemoattractant Protein-1 Is an Independent Predictor of Coronary Artery Ectasia in Patients with Acute Coronary Syndrome. J Clin Med. 2020;9(9):3-37. doi:10.3390/jcm9093037.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rajani SF, Imani A, Faghihi M, et al. Post-infarct morphine treatment mitigates left ventricular remodeling and dysfunction in a rat model of ischemia-reperfusion. Eur J Pharmacol. 2019;847:61-71. doi:10.1016/j.ejphar.2019.01.023.</mixed-citation><mixed-citation xml:lang="en">Rajani SF, Imani A, Faghihi M, et al. Post-infarct morphine treatment mitigates left ventricular remodeling and dysfunction in a rat model of ischemia-reperfusion. Eur J Pharmacol. 2019;847:61-71. doi:10.1016/j.ejphar.2019.01.023.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Gregg LP, Tio MC, Li X, et al. Association of Monocyte Chemoattractant Protein-1 with Death and Atherosclerotic Events in Chronic Kidney Disease. Am J Nephrol. 2018;47(6):395-405. doi:10.1159/000488806.</mixed-citation><mixed-citation xml:lang="en">Gregg LP, Tio MC, Li X, et al. Association of Monocyte Chemoattractant Protein-1 with Death and Atherosclerotic Events in Chronic Kidney Disease. Am J Nephrol. 2018;47(6):395-405. doi:10.1159/000488806.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Spinetti G, Wang M, Monticone R, et al. Rat aortic MCP-1 and its receptor CCR2 increase with age and alter vascular smooth muscle cell function. Arterioscler Thromb Vasc Biol. 2004;24(8):1397-402. doi:10.1161/01.ATV.0000134529.65173.08.</mixed-citation><mixed-citation xml:lang="en">Spinetti G, Wang M, Monticone R, et al. Rat aortic MCP-1 and its receptor CCR2 increase with age and alter vascular smooth muscle cell function. Arterioscler Thromb Vasc Biol. 2004;24(8):1397-402. doi:10.1161/01.ATV.0000134529.65173.08.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">DeLeon-Pennell KY, Meschiari CA, Jung M, Lindsey ML. Matrix Metalloproteinases in Myocardial Infarction and Heart Failure. Progress in Molecular Biology and Translational Science. 2017;147:75-100. doi:10.1016/bs.pmbts.2017.02.001.</mixed-citation><mixed-citation xml:lang="en">DeLeon-Pennell KY, Meschiari CA, Jung M, Lindsey ML. Matrix Metalloproteinases in Myocardial Infarction and Heart Failure. Progress in Molecular Biology and Translational Science. 2017;147:75-100. doi:10.1016/bs.pmbts.2017.02.001.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Provenzano M, Andreucci M, Garofalo C, et al. The Association of Matrix Metalloproteinases with Chronic Kidney Disease and Peripheral Vascular Disease: A Light at the End of the Tunnel? Biomolecules. 2020;10(1):154. doi:10.3390/biom10010154.</mixed-citation><mixed-citation xml:lang="en">Provenzano M, Andreucci M, Garofalo C, et al. The Association of Matrix Metalloproteinases with Chronic Kidney Disease and Peripheral Vascular Disease: A Light at the End of the Tunnel? Biomolecules. 2020;10(1):154. doi:10.3390/biom10010154.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Pasterkamp G, Schoneveld AH, Hijnen DJ, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis. 2000;150:245-53. doi:10.1016/S0021-9150(99)00371-8.</mixed-citation><mixed-citation xml:lang="en">Pasterkamp G, Schoneveld AH, Hijnen DJ, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis. 2000;150:245-53. doi:10.1016/S0021-9150(99)00371-8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Eckhard U, Huesgen PF, Schilling O, et al. Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses. Matrix Biol. 2016;49:37-60. doi:10.1016/j.matbio.2015.09.003.</mixed-citation><mixed-citation xml:lang="en">Eckhard U, Huesgen PF, Schilling O, et al. Active site specificity profiling of the matrix metalloproteinase family: Proteomic identification of 4300 cleavage sites by nine MMPs explored with structural and synthetic peptide cleavage analyses. Matrix Biol. 2016;49:37-60. doi:10.1016/j.matbio.2015.09.003.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Shogan BD, Belogortseva N, Luong PM, et al. Collagen degradation and MMP9 activation by Enterococcus faecalis contribute to intestinal anastomotic leak. Sci Transl Med. 2015;7(286):286. doi:10.1126/scitranslmed.3010658.</mixed-citation><mixed-citation xml:lang="en">Shogan BD, Belogortseva N, Luong PM, et al. Collagen degradation and MMP9 activation by Enterococcus faecalis contribute to intestinal anastomotic leak. Sci Transl Med. 2015;7(286):286. doi:10.1126/scitranslmed.3010658.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jackson HW, Defamie V, Waterhouse P, Khokha R. TIMPs: Versatile extracellular regulators in cancer. Nat Rev Cancer. 2017;17(1):38-53. doi:10.1038/nrc.2016.115.</mixed-citation><mixed-citation xml:lang="en">Jackson HW, Defamie V, Waterhouse P, Khokha R. TIMPs: Versatile extracellular regulators in cancer. Nat Rev Cancer. 2017;17(1):38-53. doi:10.1038/nrc.2016.115.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Antonov IB, Kozlov KL, Pal'tseva EM, et al. Matrix Metalloproteinases MMP-1 and MMP-9 and Their Inhibitor TIMP-1 as Markers of Dilated Cardiomyopathy in Patients of Different Age. Bull Exp Biol Med. 2018;164(4):550-3. doi:10.1007/s10517-018-4030-0.</mixed-citation><mixed-citation xml:lang="en">Antonov IB, Kozlov KL, Pal'tseva EM, et al. Matrix Metalloproteinases MMP-1 and MMP-9 and Their Inhibitor TIMP-1 as Markers of Dilated Cardiomyopathy in Patients of Different Age. Bull Exp Biol Med. 2018;164(4):550-3. doi:10.1007/s10517-018-4030-0.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ivey MJ, Talloquist MD. Defining the Cardiac Fibroblast. Circ J. 2016;80(11):2269-76. doi:10.1253/circj.CJ-16-1003.</mixed-citation><mixed-citation xml:lang="en">Ivey MJ, Talloquist MD. Defining the Cardiac Fibroblast. Circ J. 2016;80(11):2269-76. doi:10.1253/circj.CJ-16-1003.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Wang X, Khalil RA. Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. Adv Pharmacol. 2018;81:241-330. doi:10.1016/bs.apha.2017.08.002.</mixed-citation><mixed-citation xml:lang="en">Wang X, Khalil RA. Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. Adv Pharmacol. 2018;81:241-330. doi:10.1016/bs.apha.2017.08.002.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Ferretti G, Bacchetti T, Banach M, et al. Impact of Statin Therapy on Plasma MMP-3, MMP-9, and TIMP-1 Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Angiology. 2017;68(10):850-62. doi:10.1177/0003319716688301.</mixed-citation><mixed-citation xml:lang="en">Ferretti G, Bacchetti T, Banach M, et al. Impact of Statin Therapy on Plasma MMP-3, MMP-9, and TIMP-1 Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Angiology. 2017;68(10):850-62. doi:10.1177/0003319716688301.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Jobin PG, Butler GS, Overall CM. New intracellular activities of matrix metalloproteinases shine in the moonlight. Biochim. Biophys. Acta Mol Cell Res. 2017;1864(11):2043-55. doi:10.1016/j.bbamcr.2017.05.013.1864.</mixed-citation><mixed-citation xml:lang="en">Jobin PG, Butler GS, Overall CM. New intracellular activities of matrix metalloproteinases shine in the moonlight. Biochim. Biophys. Acta Mol Cell Res. 2017;1864(11):2043-55. doi:10.1016/j.bbamcr.2017.05.013.1864.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Hofbauer TM, Ondracek AS, Mangold A, et al. Neutrophil extracellular traps induce MCP-1 at the culprit site in ST-segment elevation myocardial infarction. Front Cell Dev Biol. 2020;8:564169. doi:10.3389/fcell.2020.564169.</mixed-citation><mixed-citation xml:lang="en">Hofbauer TM, Ondracek AS, Mangold A, et al. Neutrophil extracellular traps induce MCP-1 at the culprit site in ST-segment elevation myocardial infarction. Front Cell Dev Biol. 2020;8:564169. doi:10.3389/fcell.2020.564169.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
